Bibliography
- EHLERT JE: Chemokines and chemokine : disease targets for therapeutic development. Expert Opin. Invest. Drugs (2000) 9:627–629.
- •Good review of the therapeutic potential of chemokine antagonism.
- ONUFFER JJ, HORUK R: Chemokines, chemokine receptors and small-molecule antagonists: recent developments. Phannacol. Sri. (2002) 23:459–467.
- ••Very useful recent review of the literature.
- BARNES PJ: Potential novel therapies forchronic obstructive pulmonary disease. Novartis Found. Symp (2001) 234:255-267; discussion 267–272.
- WILLIAMS TJ, JOSE PJ: Neutrophils inchronic obstructive pulmonary disease. Novartis Found. Symp (2001) 234:136-141; discussion 141–148.
- BOISVERT WA, CURTISS LK, TERKELTAUB RA: Interleuldn-8 and its receptor CXCR2 in atherosclerosis. Inonunol. Res (2000) 21(2-3):129–137.
- PODOLIN PL, BOLOGNESE BJ, FOLEY JJ et al: A potent and selective non-peptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J. Inununol. (2002) 169:6435–6454.
- •Highlighting the potential of CXCR2 antagonists in arthritis.
- JIE JACK LI: Small molecule interleukin-8. Expert Opin. Ther. Patents(2001) 11:1905–1910.
- ••Recent review of CXCR2 and CXCR1 and the patent literature.
Websites
- www.astrazenecaa.com/downloads/ HY- 192002-pipeline.pdf